Tirzepatide and Cardiovascular Risk Reduction: What the Data Shows (2026)

Clinical Trial Results: SURPASS-CVOT

The SURPASS-CVOT trial, whose results were reported in 2025, evaluated tirzepatide's cardiovascular effects in more than 13,000 patients with type 2 diabetes and established atherosclerotic cardiovascular disease. Unlike placebo-controlled studies, SURPASS-CVOT compared tirzepatide head-to-head against dulaglutide, a GLP-1 receptor agonist that had already demonstrated cardiovascular benefit in the REWIND trial.

SURMOUNT-MMO: Cardiovascular Outcomes in Obesity

The SURMOUNT-MMO (Major Morbidity and Mortality Outcomes) trial represents a landmark study examining tirzepatide's cardiovascular effects specifically in patients with obesity who do not have diabetes. This trial is particularly significant because it addresses the question of whether tirzepatide's cardiovascular benefits extend beyond its glucose-lowering effects, which was the primary mechanism studied in earlier cardiovascular outcome trials.

The trial enrolled patients with established cardiovascular disease or multiple cardiovascular risk factors and a BMI of 27 or greater, randomizing them to tirzepatide or placebo. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and coronary revascularization. This expanded four-point MACE endpoint captures a broader range of cardiovascular events than the traditional three-point MACE used in diabetes trials.

SURMOUNT-MMO is still underway, with primary results expected around 2027. If the trial confirms that tirzepatide reduces major cardiovascular events in people with obesity who do not have diabetes, it would establish that the cardiovascular benefits are mediated through weight loss, anti-inflammatory effects, and potentially direct vascular effects rather than solely through glucose control. That outcome would have important implications for tirzepatide as a cardiovascular risk reduction tool in the much larger population of patients with obesity who face elevated cardiovascular risk due to excess weight and its metabolic consequences.

Biomarker Improvements: Beyond Weight and Blood Sugar

Tirzepatide produces improvements across a wide array of cardiovascular biomarkers, many of which are independent predictors of heart disease risk. Understanding these changes helps explain why the cardiovascular benefits of tirzepatide extend beyond what would be expected from weight loss alone and provides insight into the medication's multiple mechanisms of cardiovascular protection.

High-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation and an independent predictor of cardiovascular events, decreases by 30-40% in patients taking tirzepatide. This reduction is clinically meaningful because chronic low-grade inflammation is now recognized as a central driver of atherosclerotic cardiovascular disease, contributing to plaque formation, plaque instability, and thrombotic events. The magnitude of hsCRP reduction with tirzepatide is comparable to that achieved with dedicated anti-inflammatory therapies and significantly exceeds what would be expected from weight loss alone, suggesting a direct anti-inflammatory effect of the medication.

Apolipoprotein B (ApoB), which reflects the total number of atherogenic lipoprotein particles in the blood, shows significant reductions with tirzepatide treatment. ApoB is increasingly recognized as a more accurate predictor of cardiovascular risk than LDL cholesterol alone because it captures all cholesterol-carrying particles that can infiltrate the arterial wall. Tirzepatide's effect on ApoB, combined with its substantial reduction in triglycerides (20-30%) and modest improvement in HDL cholesterol, produces a comprehensively improved lipid profile that reduces atherosclerotic risk at multiple levels.

Additional biomarker improvements include reductions in liver enzymes (ALT and AST), which reflect decreased hepatic fat content and improved liver function; decreases in uric acid levels, which may reduce gout risk and have been associated with cardiovascular protection; and improvements in adiponectin, an anti-inflammatory hormone produced by fat tissue that promotes insulin sensitivity and has direct cardioprotective effects. Collectively, these biomarker changes represent a comprehensive improvement in cardiometabolic health that reduces risk through multiple complementary pathways.

How Tirzepatide Protects the Heart

Tirzepatide's cardiovascular benefits result from multiple complementary mechanisms:

Weight Loss Effect

• Significant reduction: 20.9% average body weight loss at the 15mg dose over 72 weeks in SURMOUNT-1 (individual results vary)
• Reduced cardiac workload: Less strain on heart with lower body mass
• Improved cardiac structure: Decreased left ventricular mass
• Better cardiac function: Improved ejection fraction in some patients

Blood Pressure Improvements

Lipid Profile Improvements

• Triglycerides: 20-30% reduction
• LDL Cholesterol: 5-10% reduction
• HDL Cholesterol: 5-8% increase
• Total Cholesterol: 8-12% reduction
• ApoB (atherogenic particles): Significant reduction

Compare with semaglutide's blood pressure effects and detailed cholesterol impact.

Comparison With Semaglutide SELECT Trial

The semaglutide SELECT trial, published in 2023, was the first GLP-1 receptor agonist cardiovascular outcomes trial in patients with overweight or obesity without diabetes. It demonstrated a 20% reduction in MACE, setting a high bar for cardiovascular efficacy in this population. Comparing the SELECT results with tirzepatide's cardiovascular data provides important context for clinicians and patients deciding between these medications.

Both medications demonstrate clinically significant cardiovascular benefit, but the trials are not directly comparable. SELECT tested semaglutide against placebo and found a 20% MACE reduction, while SURPASS-CVOT tested tirzepatide against dulaglutide, an active comparator that itself reduces cardiovascular events, and found an 8% lower relative MACE rate. Tirzepatide's completed cardiovascular outcome trial enrolled patients with type 2 diabetes, while SELECT focused exclusively on overweight and obese patients without diabetes. These design and population differences make head-to-head efficacy conclusions premature.

Where tirzepatide appears to have an advantage is in the magnitude of weight loss and metabolic improvement. Greater weight loss (20.9% in SURMOUNT-1 versus 14.9% in STEP 1) may translate into more pronounced improvements in certain cardiovascular risk factors, particularly blood pressure, triglycerides, and inflammatory markers. Whether this translates into a meaningful difference in hard cardiovascular endpoints remains to be determined by future head-to-head trials.

Anti-Inflammatory Effects

Chronic inflammation is a key driver of cardiovascular disease. Tirzepatide significantly reduces inflammatory markers:

Learn more about tirzepatide's anti-inflammatory effects.

Patient Selection: Who Benefits Most from Tirzepatide for CVD Risk Reduction

While tirzepatide provides cardiovascular benefits across a broad population of patients with overweight and obesity, certain patient profiles derive the greatest absolute benefit. Identifying these patients allows clinicians to prioritize tirzepatide prescribing for those who stand to gain the most from treatment, which is particularly relevant given ongoing access and cost considerations.

Patients with established atherosclerotic cardiovascular disease represent the highest-benefit group. Those with a history of myocardial infarction, stroke, peripheral artery disease, or coronary revascularization are at highest risk for recurrent events, and the absolute risk reduction from tirzepatide is greatest in this population. Similarly, patients with multiple cardiovascular risk factors including obesity, type 2 diabetes, hypertension, and dyslipidemia benefit from tirzepatide's ability to simultaneously address multiple risk factors with a single medication, potentially simplifying treatment regimens and improving overall cardiometabolic health.

Patients with metabolic syndrome, defined by the presence of three or more of the following criteria (waist circumference above threshold, elevated triglycerides, reduced HDL cholesterol, elevated blood pressure, and elevated fasting glucose), represent another group that may derive disproportionate benefit from tirzepatide. The medication addresses essentially every component of metabolic syndrome simultaneously, which no other single agent can accomplish to the same degree.

Timeline of Cardiovascular Benefits

• Weeks 1-4: Blood pressure begins to decrease
• Weeks 4-12: Blood sugar improvements, weight loss starts
• Weeks 12-24: Lipid profile improvements, reduced inflammation
• Months 6-12: Significant weight loss, cumulative CV risk reduction
• 12+ Months: Continued benefits with sustained treatment

The Bottom Line

Tirzepatide offers significant cardiovascular benefits beyond weight loss alone. With SURPASS-CVOT showing cardiovascular protection at least comparable to dulaglutide, improvements in multiple CV risk factors, and a favorable safety profile, it represents an important therapeutic option for patients with obesity and cardiovascular risk.

Explore related topics: comprehensive heart health guide and long-term cardiovascular benefits.